LakeShore Biopharma Slashes Merger Price in Amended Going-Private Deal

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks LakeShore Biopharma ( (LSBCF) ) has provided an update. On April 29, 2026, LakeShore Biopharma announced it had entered into an amended merger agreement with Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc., revising a going-private deal first signed in November 2025. Under the revised terms, Oceanpine’s Merger Sub will merge into LakeShore Biopharma in a transaction implying an equity value of about US$2.7 million, with the company to become a wholly owned subsidiary of Oceanpine Skyline and to delist from the OTC Pink Open Market if the deal closes. The amendment sharply cuts the per-share merger consideration from US$0.90 to US$0.066, though the new price still represents a roughly 46.7% premium to the March 24, 2026 closing price and a 23.3% premium to the 10-day volume-weighted average up to that date. The revised agreement also extends the termination date by nine months and lowers termination fees, while securing funding through Oceanpine Capital’s cash contribution and equity rollovers, and it is backed by a shareholder group controlling about 53.35% of voting rights, with closing targeted for the third quarter of 2026 subject to customary approvals. Spark’s Take on LSBCF Stock According to Spark, TipRanks’ AI Analyst, LSBCF is a Underperform. The score is driven primarily by weak financial performance—ongoing losses and negative operating/free cash flow outweigh strong gross margins and improving leverage trends. Technicals add additional pressure due to a pronounced downtrend and negative MACD, with only a partial offset from oversold RSI levels. Valuation cannot be meaningfully assessed given missing P/E and dividend yield data. To see Spark’s full report on LSBCF stock, click here. More about LakeShore Biopharma LakeShore Biopharma, formerly YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It operates in China, Singapore, and the Philippines, leveraging its proprietary PIKA® immunomodulating technology platform to advance biologics targeting rabies, hepatitis B, influenza, and other viral infections. Average Trading Volume: 11,943 Technical Sentiment Signal: Strong Sell Current Market Cap: $1.15M